ES2642892T3 - Protección de vacuna multivalente contra la infección por estafilococo aureus - Google Patents

Protección de vacuna multivalente contra la infección por estafilococo aureus Download PDF

Info

Publication number
ES2642892T3
ES2642892T3 ES13757330.9T ES13757330T ES2642892T3 ES 2642892 T3 ES2642892 T3 ES 2642892T3 ES 13757330 T ES13757330 T ES 13757330T ES 2642892 T3 ES2642892 T3 ES 2642892T3
Authority
ES
Spain
Prior art keywords
aureus
staphylococcus aureus
infection
vaccine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13757330.9T
Other languages
English (en)
Spanish (es)
Inventor
Mark Shirtliff
Janette HARRO
Jeffrey Leid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
University of Maryland, College Park
Original Assignee
University of Maryland, Baltimore
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore, University of Maryland, College Park filed Critical University of Maryland, Baltimore
Application granted granted Critical
Publication of ES2642892T3 publication Critical patent/ES2642892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES13757330.9T 2012-03-05 2013-03-05 Protección de vacuna multivalente contra la infección por estafilococo aureus Active ES2642892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606750P 2012-03-05 2012-03-05
US201261606750P 2012-03-05
PCT/US2013/029053 WO2013134225A1 (en) 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection

Publications (1)

Publication Number Publication Date
ES2642892T3 true ES2642892T3 (es) 2017-11-20

Family

ID=49117246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13757330.9T Active ES2642892T3 (es) 2012-03-05 2013-03-05 Protección de vacuna multivalente contra la infección por estafilococo aureus

Country Status (6)

Country Link
US (2) USRE48137E1 (enExample)
EP (1) EP2822582B1 (enExample)
JP (1) JP6204930B2 (enExample)
CA (1) CA2865620A1 (enExample)
ES (1) ES2642892T3 (enExample)
WO (1) WO2013134225A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
WO2015171693A1 (en) * 2014-05-06 2015-11-12 Virginia Commonwealth University A new target for firmicutes and related bacteria: the prp protease
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3600358A1 (en) * 2017-03-31 2020-02-05 Acell, Inc. Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CA3204730A1 (en) * 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004018624A2 (en) 2002-08-20 2004-03-04 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
EP2176662B1 (en) 2007-07-30 2012-03-28 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And Behalf Of Methods and devices for the detection of biofilm
US8318180B2 (en) 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens

Also Published As

Publication number Publication date
CA2865620A1 (en) 2013-09-12
EP2822582A4 (en) 2015-12-30
WO2013134225A1 (en) 2013-09-12
US9265820B2 (en) 2016-02-23
EP2822582A1 (en) 2015-01-14
JP6204930B2 (ja) 2017-09-27
USRE48137E1 (en) 2020-08-04
EP2822582B1 (en) 2017-09-13
US20150024000A1 (en) 2015-01-22
JP2015510883A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
Kurlenda et al. Alternative therapies in Staphylococcus aureus diseases
EP2822582B1 (en) Multivalent vaccine protection from staphylococcus aureus infection
Chen et al. Efficient and durable vaccine against intimin β of diarrheagenic E. coli induced by clay nanoparticles
JP6632974B2 (ja) フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物
EP2785368B1 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
EP2344189B1 (en) Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
WO2013032964A1 (en) Compositions and methods for preventing and treating biofilms
JP2014521605A5 (enExample)
Fan et al. Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids
JP2014507142A (ja) α溶血素オリゴペプチドを含む免疫原性組成物
ES2444693T3 (es) Polipéptido derivado de enterococo y su uso para vacunación
Li et al. Intranasal immunization with a rNMB0315 and combination adjuvants induces protective immunity against Neisseria meningitidis serogroup B in mice
MX2023011640A (es) Composiciones de vacuna de staphylococcus aureus.
JP2023509062A (ja) 黄色ブドウ球菌感染の予防のための組成物および方法
WO2024153585A1 (en) Selective caspase-8 inhibitors and uses thereof in augmenting innate immune defenses
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
Fan et al. A cleaved adhesin DNA vaccine targeting dendritic cell against Porphyromonas gingivalis–induced periodontal disease
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
JP2013090574A (ja) ペプチドワクチン
Abedini et al. A review of designing new vaccines to prevent hospital-acquired antibiotic-resistant infections
Majelan et al. Recombinant Staphylococcal Antigen-F (r-ScaF), a novel vaccine candidate against methicillin resistant Staphylococcus aureus infection: Potency and efficacy studies
KR20190139209A (ko) 면역시스템을 조절하기 위한 면역원성 조성물 및 개체에서의 세균 감염 치료 방법
Hassanzadeh Enhanced immunogenicity of Staphylococcus aureusIsdE vaccine with SeNPs and BCG adjuvants in mice
US20160120969A1 (en) Combination vaccine
Chong Review of approaches to caries treatment